Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Jamtani I.; Lalisang T.J.M.; Mulyawan W.
Jamtani, Indah (57220165203); Lalisang, Toar Jean Maurice (36623976300); Mulyawan, Wawan (57192910410)
57220165203; 36623976300; 57192910410
Effect of neoadjuvant transarterial chemoembolization followed by resection versus upfront liver resection on the survival of single large hepatocellular carcinoma patients: A systematic review and meta-analysis
2024
Annals of Hepato-Biliary-Pancreatic Surgery
28
3
325
336
11
0
Digestive Surgery Division, Department of Surgery, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Indonesian College of Digestive Surgery, Jakarta, Indonesia; Indonesian Air Force Institute of Aviation Medicine, Jakarta, Indonesia
Jamtani I., Digestive Surgery Division, Department of Surgery, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Lalisang T.J.M., Digestive Surgery Division, Department of Surgery, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia, Indonesian College of Digestive Surgery, Jakarta, Indonesia; Mulyawan W., Indonesian Air Force Institute of Aviation Medicine, Jakarta, Indonesia
Backgrounds/Aims: The efficacy of neoadjuvant transarterial chemoembolization (N−TACE) in resectable hepatocellular carcinoma (HCC) remains open to debate. While N−TACE may reduce tumor size, its impact on long-term outcomes is inconclusive. Methods: This meta-analysis reviewed studies on N−TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases. Results: Five studies with 1,556 patients were analyzed. No significant differences between N−TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N−TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N−TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N−TACE in the combination group. Conclusions: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N−TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited. © The Korean Association of Hepato-Biliary-Pancreatic Surgery.
Hepatectomy; Hepatocellular carcinoma; Liver resection; Neoadjuvant TACE; SLHCC
Korean Association of Hepato-Biliary-Pancreatic Surgery
25085778
Article
Q3
212
19286